Figure 3.
Clinical-molecular risk model. (A) Risk model for systemic mastocytosis based on HR-weighted risk points: (1) advanced SM vs ISM/SSM (HR, 4.0; 2 points); (2) age >60 years (HR, 2.2; 1 point); (3) platelets <150 × 109/L (HR, 2.8; 1 point); (4) serum ALP above normal range (HR, 2.1; 1 point); and (5) adverse mutations (HR, 2.6; 1 point). HR (95% CI) values listed are calculated against the next lower risk level. (B) Application of the clinical-molecular risk model in advanced SM. HR (95% CI) values listed are calculated against the next lower risk level.